软组织肉瘤的 II 期研究：重新评估的时机。
Phase II studies in soft tissue sarcoma: time for reappraisal.
机构信息
Department of Medical Oncology, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
出版信息
Oncologist. 2012;17(2):154-6. doi: 10.1634/theoncologist.2011-0382. Epub 2012 Jan 27.
Abstract
A phase II study with sorafenib in patients with angiosarcoma conducted by the French Sarcoma Group, and published in this issue of , is evaluated. The importance of proper design and conduct of phase II trials is stressed.
摘要
一项由法国肉瘤组织开展的索拉非尼治疗血管肉瘤的 II 期研究，发表于本期 杂志，对此进行评估。本文强调了恰当设计和开展 II 期试验的重要性。
相似文献
1
Phase II studies in soft tissue sarcoma: time for reappraisal.软组织肉瘤的 II 期研究：重新评估的时机。
Oncologist. 2012;17(2):154-6. doi: 10.1634/theoncologist.2011-0382. Epub 2012 Jan 27.
2
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).索拉非尼治疗晚期血管肉瘤患者：来自法国肉瘤集团（GSF/GETO）的 II 期试验。
Oncologist. 2012;17(2):260-6. doi: 10.1634/theoncologist.2011-0237. Epub 2012 Jan 27.
3
Objective response to sorafenib in advanced clear-cell sarcoma.索拉非尼对晚期透明细胞肉瘤的客观反应。
Ann Oncol. 2012 Mar;23(3):807-809. doi: 10.1093/annonc/mds005. Epub 2012 Jan 24.
4
Sorafenib is active on lung metastases from synovial sarcoma.索拉非尼对滑膜肉瘤的肺转移灶有效。
Ann Oncol. 2009 Feb;20(2):386-7. doi: 10.1093/annonc/mdn685.
5
About sorafenib in castration-resistant prostate cancer.关于索拉非尼在去势抵抗性前列腺癌中的应用。
Ann Oncol. 2008 Oct;19(10):1812-3; author reply 1813-1814. doi: 10.1093/annonc/mdn546. Epub 2008 Aug 9.
6
Sorafenib and sunitinib.索拉非尼和舒尼替尼。
Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.
7
Sorafenib for HCC: a pragmatic perspective.索拉非尼用于肝癌治疗：务实的视角
Oncology (Williston Park). 2011 Mar;25(3):300, 302.
8
Targeting ELF in therapy of liver cancer.以ELF为靶点治疗肝癌。
Cancer Biol Ther. 2007 Jul;6(7):997.
9
Sorafenib [corrected] in kidney cancer.索拉非尼用于肾癌治疗。
Ann Oncol. 2007 Jul;18 Suppl 9:ix90-3. doi: 10.1093/annonc/mdm301.
10
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.索拉非尼在日本肝细胞癌治疗中的应用：早期经验及对临床实践的影响。
Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.
引用本文的文献
1
Management of Cutaneous Angiosarcoma: an Update Review.皮肤血管肉瘤的管理：最新综述
Curr Treat Options Oncol. 2022 Feb;23(2):137-154. doi: 10.1007/s11864-021-00933-1. Epub 2022 Feb 19.
2
Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical Course.脾脏原发性血管肉瘤：罕见诊断与非典型临床病程
Case Rep Oncol Med. 2016;2016:4905726. doi: 10.1155/2016/4905726. Epub 2016 Oct 27.
3
Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.叉头框蛋白M1（FOXM1）表达在血管肉瘤中的预后意义及FOXM1抑制的抗肿瘤作用
J Cancer. 2016 Apr 27;7(7):823-30. doi: 10.7150/jca.14461. eCollection 2016.
4
Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.头面部皮肤血管肉瘤：日本43例患者治疗结果的单中心分析
J Cancer Res Clin Oncol. 2016 Jun;142(6):1387-94. doi: 10.1007/s00432-016-2151-2. Epub 2016 Mar 25.
本文引用的文献
1
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).PALETTE 研究：既往化疗期间或之后疾病进展的软组织肉瘤患者中，帕唑帕尼与安慰剂的随机、双盲、III 期临床试验结果-欧洲癌症研究与治疗组织软组织和骨肉瘤研究组全球网络研究（EORTC 62072）
Cancer. 2015 Sep 1;121(17):2933-41. doi: 10.1002/cncr.29426. Epub 2015 May 29.
2
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).索拉非尼治疗晚期血管肉瘤患者：来自法国肉瘤集团（GSF/GETO）的 II 期试验。
Oncologist. 2012;17(2):260-6. doi: 10.1634/theoncologist.2011-0237. Epub 2012 Jan 27.
3
Role of chemotherapy in the management of soft tissue sarcomas.化疗在软组织肉瘤治疗中的作用。
Expert Rev Anticancer Ther. 2010 Feb;10(2):249-60. doi: 10.1586/era.09.176.
4
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.人类血管肉瘤中的KDR激活突变对特定激酶抑制剂敏感。
Cancer Res. 2009 Sep 15;69(18):7175-9. doi: 10.1158/0008-5472.CAN-09-2068. Epub 2009 Sep 1.
5
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.采用实体瘤疗效评价标准评估的疾病无进展可预测晚期胃肠道间质瘤患者接受甲磺酸伊马替尼治疗后的生存情况：EORTC-ISG-AGITG 国际 III 期试验。
J Clin Oncol. 2009 Aug 20;27(24):3969-74. doi: 10.1200/JCO.2008.21.3330. Epub 2009 Jul 20.
6
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.索拉非尼用于转移性或复发性肉瘤患者的II期研究。
J Clin Oncol. 2009 Jul 1;27(19):3133-40. doi: 10.1200/JCO.2008.20.4495. Epub 2009 May 18.
7
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).帕唑帕尼，一种多激酶血管生成抑制剂，用于复发或难治性晚期软组织肉瘤患者：一项来自欧洲癌症研究与治疗组织-软组织和骨肉瘤组的II期研究（EORTC研究62043）。
J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
9
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.无进展率作为软组织肉瘤II期试验的主要终点。
Eur J Cancer. 2002 Mar;38(4):543-9. doi: 10.1016/s0959-8049(01)00398-7.
Zotero 插件